Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Indian Avastin Versions Head For Debut; Watch Off-Label Space

Executive Summary

Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.


Related Content

Litigation Aside Biosimilar Avastin Just Got Cheaper In India
Indian Avastin Biosimilar Arrives Amid Roche's Charges
Roche Backs Off Mircera Suit In India
Indian Herceptin Biosimilars Case Simmers
India Avastin Off-Label Use: Roche Defines Responsibility
Novartis-Intas Ranibizumab Settlement Sets Liability For Breach
Intas' biosimilar Enbrel debuts at hefty discount in India


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst